Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
Received 1 March 2018
Accepted for publication 7 April 2018
Published 22 May 2018 Volume 2018:12 Pages 887—897
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Naifeng Liu
Pin Gao,1 Lili You,2 Di Wu,1 Aiping Shi,1 Qing Miao,3 Ujala Rana,4 Dustin Paul Martin,3 Ye Du,1 Gang Zhao,1 Bing Han,1 Chao Zheng,5 Zhimin Fan1
1Department of Breast Surgery, First Hospital of Jilin University, Changchun, Jilin, China; 2Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; 3Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; 4Division of Neonatology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA; 5Department of Breast Surgery, Second Hospital of Shandong University, Jinan, Shandong, China
Background: Postoperative endocrine therapy is known to reduce recurrence and mortality in patients with estrogen receptor (ER)- or progestogen receptor (PR)-positive breast cancer. Correlates and determinants of compliance with endocrine therapy among Chinese patients with breast cancer are not known. The aim of this study was to elucidate the efficacy and adherence of endocrine therapy in China and suggest effective improvements on the adherence.
Patients and methods: We analyzed the survival of 1,110 patients eligible for endocrine therapy and adherence of 699 patients to endocrine therapy. Kaplan–Meier curves, log-rank tests and Cox proportional hazard models were used to evaluate survival, and logistic regression models were used to assess variables associated with treatment adherence.
Results: Long-term endocrine therapy was associated with lower recurrence rate (HR 0.72; 95% CI 0.56–0.93; p=0.013). Adherence to endocrine therapy was only 63.1%. Sociodemographic characteristics of patients, clinical- and medication-related characteristics and patients’ attitudes were associated with adherence to endocrine therapy.
Conclusion: Adherence to endocrine therapy in Chinese patients with ER+/PR+ breast cancer was <65%. Both patients and physicians should take progressive steps to improve the rate of adherence.
Keywords: breast cancer, endocrine therapy, adherence
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]